The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Statement 6.5
“Hospital pharmacists should be actively involved in clinical trials of medicines.”
What does it mean for patients? Patients can contribute to the development of new drugs by providing their informed consent to participate in a trial; testing of new medicines under the supervision of the principal investigator and a hospital pharmacist, who checks the quality and safety of the products. The hospital pharmacist is responsible for the preparation and distribution of these investigational medicines.
What does it mean for healthcare professionals? Hospital pharmacists can be relied on to establish safe procedures and protocols to comply with legislation concerning the use of the investigational medicines and their management.
What does it mean for Hospital Pharmacists? Hospital pharmacists should actively participate in the management of clinical trials and be responsible for the accountability, the preparation and the distribution of the investigational medicines.
The SindelfingenBoeblingen Medical Center is SILCC Host providing training on this Statement. Please learn more about the SILCC programme here.
- GPI: IMPROVING INVESTIGATIONAL DRUG MANAGEMENT: AN INNOVATIVE PROCESS
- EAHP STATEMENT ON CLINICAL TRIALS
- EAHP Policy Statement on Antimicrobial Resistance
- EAHP Survey Report 2015
- GPI: eLearning Environment for Ensuring the Competence in Pharmacotherapy
- GPI: A 72 hours training program for pharmacy residents to perform secure, optimised and standardized medication review orders: a proof of concept
- GPI:INTRODUCTION OF A PATIENT- CENTRED CLINICAL PHARMACY TRAINING SCHEME IN A LARGE UNIVERSITY HOSPITAL PHARMACY
- EAHP Brochure